New Jersey Joins in Closing Hemp Loophole –New Legislation Regulates Hemp-Derived Products

On January 12, 2026, Governor Phil Murphy signed Senate Bill 4509 into law, ushering in a sweeping reform of New Jersey’s hemp laws and establishing a regulatory framework for intoxicating hemp products (“IHPS”) that have proliferated across the Garden State. The bill’s sponsors aimed to close a long-standing loophole created by the 2018 federal Farm Bill, which permitted IHPs to be sold widely with no oversight. The enactment of SB 4509 represents the latest and most consequential chapter in New Jersey’s multi-year effort to regulate these products.

Two years ago, New Jersey attempted to regulate IHPs but its efforts were unsuccessful. In September 2024, New Jersey enacted legislation prohibiting the sale of IHPs to minors and imposing new restrictions on their distribution. Just days before the law was scheduled to take effect, a federal judge issued a permanent injunction blocking most of its substantive provisions.  In Loki Brands LLC v. Platkin, the District Court of New Jersey held that the law’s definition of “intoxicating hemp products” expressly discriminated against out-of-state hemp by prohibiting its sale in New Jersey. The court concluded that the law violated the Dormant Commerce Clause by penalizing out-of-state producers and manufacturers. It further held that the statute conflicted with—and was, therefore, preempted by—the 2018 Farm Bill because it effectively transformed federally legal hemp into a controlled substance simply by virtue of being shipped through New Jersey.

The federal landscape concerning hemp has dramatically shifted since Loki was decided.  As part of the 2025 federal spending bill, Congress overhauled federal hemp standards by including a provision banning the sale of any hemp-derived THC product containing more than 0.3% total THC—not just delta-9 THC as permitted under the 2018 Farm Bill—on a dry weight basis.  Congress also narrowed the definition of legal hemp to exclude products containing cannabinoids that “were synthesized or manufactured outside the plant” and prohibited consumer products containing more than 0.4 milligrams of total THC per container.  Taken together, these changes render virtually all existing IHPs unlawful under federal law.  The new federal prohibition is set to go into effect on November 13, 2026. 

New Jersey’s newly enacted law is calibrated to align with these updated federal standards.  Under SB 4509,  hemp may not contain more than 0.3% total THC, including delta-8, delta-10, THCA, and similar cannabinoids, and IHPs may not contain more than 0.4 milligrams of THC per container. Products that exceed these thresholds are deemed cannabis and fall under the jurisdiction of the New Jersey Cannabis Regulatory Commission (“CRC”). As a result, the sale of such products will require a state-issued cannabis license and compliance with the same regulatory requirements imposed on licensed cannabis businesses operating in New Jersey. 

While the law took effect on January 13, 2026, its implementation will be a phased approach.  To allow the CRC time to develop its regulatory scheme, and to mitigate the economic impact on existing IHP retailers, the statute provides a grace period through April 13, 2026, during which time current sellers must liquidate their inventory.  The law does, however, carve out a narrow exception for intoxicating hemp beverages, which may continue to be sold at licensed liquor stores until November 13, 2026  when the federal prohibition goes into effect.  At that point, any beverage exceeding the new THC limits will be regulated as cannabis. 

With the passage of SB 4509, New Jersey has signaled an end to the sale of unregulated IHPs.  By harmonizing New Jersey law with federal hemp rules and addressing the constitutional defects identified in Loki, the Legislature has likely crafted a framework designed to withstand legal scrutiny while prioritizing consumer safety and regulatory clarity.

Steady Hands at the Tiller – New NJCRC Executive Director Appointed

New Jersey Governor Murphy announced yesterday that current NJCRC Executive Director Jeff Brown is returning to the New Jersey Department of Health to take on the role of Deputy Commissioner for Healthcare Systems, effective May 20, 2024.

Current NJCRC Deputy Executive Director and former General Counsel Christopher Riggs will assume the role of acting Executive Director upon Brown’s departure.

Brown has served as the Executive Director since the formation of the NJCRC in April 2021, and before that as Assistant Commissioner for the Division of Medicinal Marijuana at the New Jersey Department of Health since 2018.

Despite the inevitable friction and challenges associated with this nascent field and reporting to a board of very active, full time commissioners, Brown has proven a steady hand at the tiller both at NJDOH and at NJCRC. Throughout his tenure in both agencies, Brown has been instrumental in the development and implementation of New Jersey’s medical and recreational laws and rules. He led the reinvention of New Jersey’s moribund-by-design medical marijuana program, and then stood up the NJCRC as a new agency to regulate both adult-use and medicinal cannabis. Under Brown’s leadership, New Jersey’s cannabis market has grown each year with 2024 cannabis sales expected to top $1 billion.

Though Brown will be a hard act to follow, Acting Executive Director Riggs is expected to be another steady hand at the tiller leading regulation of the market. Well-equipped to assume the role of Executive Director, Riggs has worked for the NJCRC since its inception.  He initially served as the NJCRC’s first chief counsel and led the drafting and promulgation of the laws and rules that govern the industry. Before that, he was a Deputy Attorney General in the Office of the Attorney General and was assistant chief of the section representing the Department of Health and Human Services.

Well regarded among attorneys and industry veterans alike, it is expected Riggs and the NJCRC will now focus on streamlining and rationalizing regulatory processes to improve oversight and reduce bureaucratic delay and red tape. Riggs has also indicated he intends to prioritize clinical registrant applications and social equity certification process at the NJCRC.

We wish both well in their new roles.

NJ Cannabis – 3Q 2022 Adult Use Sales Numbers Continue to Blaze


According to recent reporting from the NJ Cannabis Regulatory Commission (“NJCRC”), sales of legalized, recreational adult use cannabis in NJ exceeded $116.5 Million from July to September of 2022. This Q3 revenue figure represents a 46% increase from sales receipts in Q2 of 2022 of $80 Million generated from April to June 2022, when 13 state dispensaries expanded to adult cannabis sales for the first time.

By way of background, New Jersey legalized the sale of recreational marijuana for those 21 and over in April 2021. Sales were initially confined to 12 licensed dispensaries, which had approximately $24 Million in sales through May 2021, or an average of $5 Million per week in a state with 9.3 Million residents. By comparison, adult recreational cannabis generated approximately $80 Million in total sales between April and June 30 per the Cannabis Authority or $6.7M per week. Continue reading “NJ Cannabis – 3Q 2022 Adult Use Sales Numbers Continue to Blaze”

Lifting the Haze: New Jersey Cannabis Regulatory Commission Issues Interim Guidance on Drug Testing

On September 9, 2022, the New Jersey Cannabis Regulatory Commission issued interim guidance for employers on drug testing employees for cannabis. Since the legalization of recreational marijuana for adults 21 years of age or older, New Jersey employers are expected to follow certain procedures associated with drug testing employees based on reasonable suspicion of impairment. Until specific regulations are issued, the commission has provided interim guidance to clear some of the haze for employers trying to navigate compliance with New Jersey’s cannabis law.

To read the full text of this Duane Morris Alert, please visit the firm website.

© 2009- Duane Morris LLP. Duane Morris is a registered service mark of Duane Morris LLP.

The opinions expressed on this blog are those of the author and are not to be construed as legal advice.

Proudly powered by WordPress